Nahdi Medical Company (4164.SR)
SAR 114.0
(0.35%)
SAR 114.0
(0.35%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.9 Billion SAR | 7.66% |
| 2022 | 2.7 Billion SAR | 0.68% |
| 2021 | 2.68 Billion SAR | 3.72% |
| 2020 | 2.58 Billion SAR | 7.71% |
| 2019 | 2.4 Billion SAR | 137.84% |
| 2018 | 1 Billion SAR | 6.99% |
| 2017 | 944 Million SAR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 3.18 Billion SAR | -5.28% |
| 2024 Q1 | 3.35 Billion SAR | 15.47% |
| 2023 Q2 | 2.83 Billion SAR | -20.62% |
| 2023 Q1 | 3.57 Billion SAR | 32.15% |
| 2023 FY | 2.9 Billion SAR | 7.66% |
| 2023 Q4 | 2.9 Billion SAR | 1.88% |
| 2023 Q3 | 2.85 Billion SAR | 0.73% |
| 2022 Q4 | 2.7 Billion SAR | -5.89% |
| 2022 Q3 | 2.87 Billion SAR | -0.65% |
| 2022 Q2 | 2.88 Billion SAR | -5.23% |
| 2022 Q1 | 3.04 Billion SAR | 13.62% |
| 2022 FY | 2.7 Billion SAR | 0.68% |
| 2021 FY | 2.68 Billion SAR | 3.72% |
| 2021 Q3 | 2.9 Billion SAR | 3.89% |
| 2021 Q2 | 2.79 Billion SAR | 0.0% |
| 2021 Q1 | - SAR | -100.0% |
| 2021 Q4 | 2.68 Billion SAR | -7.67% |
| 2020 Q1 | - SAR | 0.0% |
| 2020 FY | 2.58 Billion SAR | 7.71% |
| 2020 Q4 | 2.58 Billion SAR | 0.0% |
| 2019 FY | 2.4 Billion SAR | 137.84% |
| 2018 FY | 1 Billion SAR | 6.99% |
| 2017 FY | 944 Million SAR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Middle East Pharmaceutical Industries Co. | 138.49 Million SAR | -2000.063% |
| Al-Dawaa Medical Services Company | 3.39 Billion SAR | 14.315% |
| Al-Razi Medical Co. | 23.04 Million SAR | -12519.457% |
| Almujtama Alraida Medical Co. | 312.21 Million SAR | -831.598% |